The strengths of our study include the large number of patients in the study group and the use of well-established criteria for the diagnosis of IUGR, but it can, of course, be improved by the more objective and quantitative measurement of survivin in placental tissue and other samples, like umbilical or maternal blood. The gene discussed is BIRC5; the disease is fetal growth restriction.